Importer of Controlled Substances; Notice of Registration, 25374-25375 [2011-10863]
Download as PDF
<![CDATA[
25374
Federal Register / Vol. 76, No. 86 / Wesnesday, May 4, 2011 / Notices
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(d)–(e) and 210.13(a),
such responses will be considered by
the Commission if received not later
than 20 days after the date of service by
the Commission of the complaint and
the notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on February 2,
2011, Rhodes Technologies, 498
Washington Street, Coventry, Rhode
Island 02816, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the following basic
classes of controlled substances in
schedule II:
jlentini on DSKJ8SOYB1PROD with NOTICES
Schedule
I
II
The company plans to import the
listed controlled substances in order to
bulk manufacture controlled substances
in Active Pharmaceutical Ingredient
(API) form. The company distributes the
17:45 May 03, 2011
BILLING CODE 4410–09–P
Importer of Controlled Substances;
Notice of Registration
BILLING CODE P
VerDate Mar<15>2010
[FR Doc. 2011–10914 Filed 5–3–11; 8:45 am]
Drug Enforcement Administration
[FR Doc. 2011–10754 Filed 5–3–11; 8:45 am]
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
Dated: April 28, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT of JUSTICE
By order of the Commission.
Issued: April 28, 2011.
William R. Bishop,
Acting Secretary to the Commission.
Drug
manufactured APIs in bulk form only to
its customers.
As explained in the Correction to
Notice of Application pertaining to
Rhodes Technologies, 72 FR 3417
(2007), comments and requests for
hearings on applications to import
narcotic raw material are not
appropriate.
As noted in a previous notice
published in the Federal Register on
September 23, 1975, 40 FR 43745, all
applicants for registration to import a
basic classes of any controlled
substances in schedule I or II are, and
will continue to be, required to
demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Jkt 223001
By Notice dated November 18, 2010,
and published in the Federal Register
on December 3, 2010, 75 FR 75494,
Clinical Supplies Management, Inc., 342
42nd Street South, Fargo, North Dakota
58103, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites conducting
clinical trials under the auspices of an
FDA-approved clinical study.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Supplies Management, Inc., to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Clinical Supplies Management, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: April 26, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–10862 Filed 5–3–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 18, 2010,
and published in the Federal Register
on December 3, 2010, 75 FR 75495,
Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug
Noroxymorphone (9668) .......
Tapentadol (9780) ................
Schedule
II
II
The company plans to import the
listed substances for analytical research
and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and has determined that the registration
of Fisher Clinical Services, Inc. to
import the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Fisher Clinical Services, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
E:\FR\FM\04MYN1.SGM
04MYN1
Federal Register / Vol. 76, No. 86 / Wesnesday, May 4, 2011 / Notices
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
Dated: April 26, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
25375
By Notice dated November 19, 2010,
and published in the Federal Register
on December 3, 2010, 75 FR 75496,
Tocris Cookson, Inc., 16144 Westwoods
Business Park, Ellisville, Missouri
63021–4500, made application by
renewal to the Drug Enforcement
[FR Doc. 2011–10863 Filed 5–3–11; 8:45 am]
BILLING CODE 4410–09–P
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
Drug
Schedule
jlentini on DSKJ8SOYB1PROD with NOTICES
Marihuana (7360) ................................................................................................................................................................................
Tetrahydrocannabinols (7370) .............................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ......................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ....................................................................................................................................
Amphetamine (1100) ...........................................................................................................................................................................
Phencyclidine (7471) ...........................................................................................................................................................................
Cocaine (9041) ....................................................................................................................................................................................
Diprenorphine (9058) ...........................................................................................................................................................................
Fentanyl (9801) ....................................................................................................................................................................................
The company plans to import small
quantities of the above-listed controlled
substances for distribution to its
customers for non-clinical, laboratorybased research only.
In reference to drug code 7360
(Marihuana), the company plans to
import synthetic cannabinoid agonists.
In reference to drug code 7370
(Tetrahydrocannabinols), the company
will import a synthetic Delta-9-THC. No
other activity for these drug codes are
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Tocris Cookson, Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Tocris Cookson, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
VerDate Mar<15>2010
17:45 May 03, 2011
Jkt 223001
Dated: April 26, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
for conversion and sale to dosage form
manufacturers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 5, 2011.
[FR Doc. 2011–10864 Filed 5–3–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 9, 2011,
Rhodes Technologies, 498 Washington
Street, Coventry, Rhode Island 02816,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Frm 00078
Fmt 4703
[FR Doc. 2011–10853 Filed 5–3–11; 8:45 am]
BILLING CODE 4410–09–P
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
PO 00000
Dated: April 25, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Tetrahydrocannabinols (7370) ......
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ....................
Noroxymorphone (9668) ...............
Fentanyl (9801) ............................
Sfmt 4703
I
I
I
I
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 15, 2011,
Siemens Healthcare Diagnostics Inc.,
Attn: RA, 100 GBC Drive, Mail Stop 514,
Newark, Delaware 19702, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 76, Number 86 (Wednesday, May 4, 2011)]
[Notices]
[Pages 25374-25375]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10863]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated November 18, 2010, and published in the Federal
Register on December 3, 2010, 75 FR 75495, Fisher Clinical Services,
Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Noroxymorphone (9668)..................... II
Tapentadol (9780)......................... II
------------------------------------------------------------------------
The company plans to import the listed substances for analytical
research and clinical trials.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and has determined that the
registration of Fisher Clinical Services, Inc. to import the basic
classes of controlled substances is consistent with the public interest
and with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971. DEA has
investigated Fisher Clinical Services, Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
[[Page 25375]]
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named company is granted registration as
an importer of the basic classes of controlled substances listed.
Dated: April 26, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-10863 Filed 5-3-11; 8:45 am]
BILLING CODE 4410-09-P
